South Korea to roll out Novavax COVID-19 vaccine next week
South Korea will begin offering Novavax Inc.’s COVID-19 vaccine at hospitals, nursing homes and public health centers next week, adding another tool to fight a fast-developing omicron surge
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.South Korea will begin offering Novavax Inc.'s COVID-19 vaccine at hospitals, nursing homes and public health centers next week, officials said, adding another tool to fight a fast-developing omicron surge.
The country reported a record 54,122 new coronavirus cases on Thursday, according to the Korea Disease Control and Prevention Agency, a 12-fold increase from daily levels seen in mid-January, when omicron first became the country’s dominant strain.
But officials are expressing cautious hope that the country’s high vaccination rate will prevent an explosion in serious illnesses and deaths. As of Thursday, 86% of South Koreans were fully vaccinated and 56% had received booster shots under a mass immunization program that has been mainly dependent on Pfizer and Moderna’s mRNA vaccines.
Novavax’s protein vaccine, which is similar to shots used for years against diseases such as the common flu and hepatitis B, could appeal to people who are hesitant to use other COVID-19 vaccines designed with newer technologies, KDCA official Lim Sook-young said.
The shots are produced by the Maryland company’s South Korean partner, SK Bioscience, which has been contracted to manufacture 40 million doses, all of which will be used locally. Lim said SK delivered 551,000 doses on Thursday and will deliver another 294,000 doses on Friday.
“We plan to actively use the (Novavax) shots on unvaccinated people 18 years or older, especially high-risk groups including hospitalized patients, senior citizens and people with disabilities who are at larger risk of serious illness and death,” Lim said during a briefing.
South Korea has significantly eased quarantine restrictions and reshaped its COVID-19 response around at-home treatments and rapid antigen testing as it struggles to deal with an unprecedented wave of infections fueled by the fast-moving omicron variant.
The KDCA said 282 patients were in serious or critical condition as of Thursday, but the Health Ministry said less than 20% of the country’s intensive care units designated for COVID-19 treatment were occupied. Still, experts say the country’s surging caseload is likely to drive up hospitalizations in coming weeks.